aspirin has been researched along with Atheroma in 37 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 9.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 7.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "These results suggest that low dose aspirin reduces early atherosclerosis, while inhibition of COX-2 by meloxicam is not associated with an increase in atherosclerotic plaque size in this mouse model." | 7.80 | Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. ( Afek, A; Arber, N; Aroch, I; Eisenberg, O; Finkelstein, A; George, J; Kazanov, D; Kraus, S; Naumov, I; Shapira, S, 2014) |
| "Hydrogen sulfide (H(2)S) is a novel gaseous mediator that plays important roles in atherosclerosis." | 7.78 | Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice. ( Fan, Y; Gu, T; Guo, C; Sparatore, A; Wang, C; Wu, D; Zhang, A; Zhang, H, 2012) |
| "Targeting platelet-mediated thrombus formation with dual antiplatelet therapy comprising acetylsalicylic acid and a P2Y12 antagonist is the current mainstay for management of ACS." | 6.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 5.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| "We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in hemostasis." | 4.31 | Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. ( Alenazy, FO; Brady, P; Connolly, DL; Harbi, MH; Hargreaves, O; Harrison, P; Jandrot-Perrus, M; Kalia, N; Kavanagh, DP; Kirchhof, P; Mangin, PH; Nicolson, PLR; Price, J; Slater, A; Thomas, MR; Tiwari, A; Watson, SP, 2023) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 3.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "The initial EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion) demonstrated that patients with acute coronary syndrome caused by plaque erosion might be stabilized with aspirin and ticagrelor without stenting for ≤1 month." | 3.85 | EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. ( Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y, 2017) |
| "Within this retrospective observational spontaneous clinical study 44 patients (31 males and 13 females) all presenting stable coronary artery disease were evaluated; 25 subjects were treated with only acetylsalicylic acid and/or clopidogrel in association with statins (standard therapeutic protocol) while for the other 18 subjects the standard therapeutic protocol was integrated with Arnica comp." | 3.83 | Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease. ( Bianchi, M; Di Nardo, V; Fioranelli, M; Roccia, MG, 2016) |
| "In mice deficient of apolipoprotein E (Apoe-/-), aspirin (20, 50 mg/kg/day) suppressed the progression of atherosclerosis in aortic roots and increased the plaque stability in carotid atherosclerotic plaques induced by collar-placement." | 3.83 | Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo. ( Chen, Y; Li, P; Li, QZ; Liang, WJ; Ma, H; Ma, ZM; Peng, QS; Wang, F; Wang, SX; Yang, JJ; Zhang, Y, 2016) |
| "These results suggest that low dose aspirin reduces early atherosclerosis, while inhibition of COX-2 by meloxicam is not associated with an increase in atherosclerotic plaque size in this mouse model." | 3.80 | Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. ( Afek, A; Arber, N; Aroch, I; Eisenberg, O; Finkelstein, A; George, J; Kazanov, D; Kraus, S; Naumov, I; Shapira, S, 2014) |
| "Hydrogen sulfide (H(2)S) is a novel gaseous mediator that plays important roles in atherosclerosis." | 3.78 | Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice. ( Fan, Y; Gu, T; Guo, C; Sparatore, A; Wang, C; Wu, D; Zhang, A; Zhang, H, 2012) |
| "Aspirin is an effective antiplatelet agent for the treatment of carotid atherosclerosis." | 3.11 | Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised controlled trial. ( Jin, J; Liu, Y; Qu, L; Shen, X; Wu, J; Zou, S, 2022) |
| "Aspirin response test was evaluated 1 hour after aspirin intake using multiplate platelet function analyzer, and carotid ultrasonography has been performed to determine carotid intima-media thickness (CIMT) and the presence of carotid plaque." | 2.87 | The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. ( Bulut, U; Demir, AR; Kalayci, B; Karakurt, H; Karakurt, ST; Serbest, NG; Somuncu, MU, 2018) |
| "Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease." | 2.78 | Increased local cytokine production at culprit superficial femoral artery plaques. ( Adams, JE; Ashikaga, T; Bertges, DJ; Dauerman, HL; Donaldson, CW; Elgharib, NZ; Mueller, EL; Prabhu, W; Schneider, DJ, 2013) |
| "Targeting platelet-mediated thrombus formation with dual antiplatelet therapy comprising acetylsalicylic acid and a P2Y12 antagonist is the current mainstay for management of ACS." | 2.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | 2.47 | TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "Atherothrombosis, an atherosclerotic plaque disruption condition with superimposed thrombosis, is the underlying cause of cardiovascular episodes." | 1.72 | Atherothrombosis-on-Chip: A Site-Specific Microfluidic Model for Thrombus Formation and Drug Discovery. ( Adelnia, H; Akther, F; Fallahi, H; Nguyen, NT; Phan, HP; Ta, HT; Tran, HDN; Zhang, J, 2022) |
| " The aim of our study was to investigate if the Syk inhibitor fostamatinib could be repurposed as an antiplatelet drug, either alone or in combination with conventional antiplatelet therapy." | 1.72 | Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. ( Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP, 2022) |
| "Recent studies suggested protruding thrombus and atheroma after stent placement could be a substrate for subsequent adverse ischemic events." | 1.48 | Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. ( Hirata, KI; Kijima, Y; Kozuki, A; Masano, T; Nagoshi, R; Otake, H; Shibata, H; Shinke, T; Shite, J; Takeshige, R; Tsukiyama, Y; Yanaka, KI, 2018) |
| "It is a marker of atherosclerotic plaque burden and the strongest independent predictor of future myocardial infarction and mortality." | 1.46 | Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring. ( Chan, J; Chow, CK; Hamilton-Craig, CR; Jelinek, VM; Liew, GY; Younger, JF, 2017) |
| "Consecutive patients with atherosclerotic plaque detected by coronary CT angiography were enrolled in our study from September 2013 to December 2014, grouped as <50% stenosis and ≥ 50% stenosis." | 1.42 | [Influence of coronary CT angiography findings on prevention strategies of coronary artery disease]. ( Dai, R; Gao, Y; Hou, Z; Jiang, S; Li, Z; Liu, K; Lü, B; Ren, X; Wang, Z; Yin, W, 2015) |
| "Stroke is a second cause of mortality worldwide and a leading cause of acquired disability in adults." | 1.38 | [Ulcerated plaques of the aorta as a cause of ischaemic stroke]. ( Hoffman, P; Kowalski, M; Michałowska, I; Rybicka, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (75.68) | 24.3611 |
| 2020's | 9 (24.32) | 2.80 |
| Authors | Studies |
|---|---|
| Akther, F | 1 |
| Zhang, J | 1 |
| Tran, HDN | 1 |
| Fallahi, H | 1 |
| Adelnia, H | 1 |
| Phan, HP | 1 |
| Nguyen, NT | 1 |
| Ta, HT | 1 |
| Harbi, MH | 2 |
| Smith, CW | 1 |
| Alenazy, FO | 2 |
| Nicolson, PLR | 2 |
| Tiwari, A | 2 |
| Watson, SP | 2 |
| Thomas, MR | 2 |
| Shen, X | 1 |
| Zou, S | 1 |
| Jin, J | 1 |
| Liu, Y | 1 |
| Wu, J | 1 |
| Qu, L | 1 |
| Kavanagh, DP | 1 |
| Price, J | 1 |
| Brady, P | 1 |
| Hargreaves, O | 1 |
| Harrison, P | 1 |
| Slater, A | 1 |
| Connolly, DL | 1 |
| Kirchhof, P | 1 |
| Kalia, N | 1 |
| Jandrot-Perrus, M | 1 |
| Mangin, PH | 1 |
| Belcaro, G | 2 |
| Cesarone, MR | 2 |
| Scipione, C | 2 |
| Scipione, V | 2 |
| Dugall, M | 2 |
| Shu, H | 1 |
| Peterzan, P | 1 |
| Corsi, M | 1 |
| Luzzi, R | 1 |
| Hosoi, M | 1 |
| Feragalli, B | 2 |
| Cotellese, R | 2 |
| Hu, S | 2 |
| Maione, C | 1 |
| Nguyen, KA | 1 |
| Eadon, MT | 1 |
| Yoo, R | 1 |
| Milway, E | 1 |
| Kenneally, A | 1 |
| Fekete, K | 1 |
| Oh, H | 1 |
| Duong, K | 1 |
| Whipple, EC | 1 |
| Schleyer, TK | 1 |
| Schade, DS | 1 |
| Burchiel, S | 1 |
| Eaton, RP | 1 |
| Oggero, S | 1 |
| de Gaetano, M | 1 |
| Marcone, S | 1 |
| Fitzsimons, S | 1 |
| Pinto, AL | 1 |
| Ikramova, D | 1 |
| Barry, M | 1 |
| Burke, D | 1 |
| Montero-Melendez, T | 1 |
| Cooper, D | 1 |
| Burgoyne, T | 1 |
| Belton, O | 1 |
| Norling, LV | 1 |
| Brennan, EP | 1 |
| Godson, C | 1 |
| Perretti, M | 1 |
| Hamilton-Craig, CR | 1 |
| Chow, CK | 1 |
| Younger, JF | 1 |
| Jelinek, VM | 1 |
| Chan, J | 1 |
| Liew, GY | 1 |
| Soehnlein, O | 1 |
| Xing, L | 1 |
| Yamamoto, E | 1 |
| Sugiyama, T | 1 |
| Jia, H | 1 |
| Ma, L | 1 |
| Wang, C | 2 |
| Zhu, Y | 1 |
| Li, L | 1 |
| Xu, M | 1 |
| Liu, H | 1 |
| Bryniarski, K | 1 |
| Hou, J | 1 |
| Zhang, S | 1 |
| Lee, H | 1 |
| Yu, B | 1 |
| Jang, IK | 1 |
| Tsukiyama, Y | 1 |
| Kozuki, A | 1 |
| Shinke, T | 1 |
| Otake, H | 1 |
| Kijima, Y | 1 |
| Masano, T | 1 |
| Nagoshi, R | 1 |
| Shibata, H | 1 |
| Takeshige, R | 1 |
| Yanaka, KI | 1 |
| Shite, J | 1 |
| Hirata, KI | 1 |
| Somuncu, MU | 1 |
| Demir, AR | 1 |
| Karakurt, H | 1 |
| Serbest, NG | 1 |
| Kalayci, B | 1 |
| Bulut, U | 1 |
| Karakurt, ST | 1 |
| Weingärtner, O | 1 |
| Schulze, PC | 1 |
| Möbius-Winkler, S | 1 |
| Chan, NC | 1 |
| Weitz, JI | 2 |
| Fazio, S | 1 |
| Brigo, F | 1 |
| Storti, M | 1 |
| Lochner, P | 1 |
| Tezzon, F | 1 |
| Nardone, R | 1 |
| Bakri, SJ | 1 |
| Luqman, A | 1 |
| Pathik, B | 1 |
| Chandrasekaran, K | 1 |
| Amarenco, P | 1 |
| Davis, S | 1 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 1 |
| Kaste, M | 1 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| Donnan, GA | 1 |
| Kraus, S | 1 |
| Naumov, I | 1 |
| Shapira, S | 1 |
| Kazanov, D | 1 |
| Aroch, I | 1 |
| Afek, A | 1 |
| Eisenberg, O | 1 |
| George, J | 1 |
| Arber, N | 1 |
| Finkelstein, A | 1 |
| Okura, H | 1 |
| Kataoka, T | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Yoshida, K | 1 |
| Lewszuk, AJ | 1 |
| Postuła, M | 1 |
| Madycki, G | 1 |
| Staszkiewicz, W | 1 |
| Opolski, G | 1 |
| Eberhardt, A | 1 |
| Amato, B | 1 |
| Compagna, R | 1 |
| Amato, M | 1 |
| Gallelli, L | 1 |
| de Franciscis, S | 1 |
| Serra, R | 1 |
| Li, Z | 1 |
| Lü, B | 1 |
| Wang, Z | 1 |
| Liu, K | 1 |
| Hou, Z | 1 |
| Gao, Y | 1 |
| Yin, W | 1 |
| Ren, X | 1 |
| Jiang, S | 1 |
| Dai, R | 1 |
| Fioranelli, M | 1 |
| Bianchi, M | 1 |
| Roccia, MG | 1 |
| Di Nardo, V | 1 |
| Yang, JJ | 1 |
| Li, P | 1 |
| Wang, F | 1 |
| Liang, WJ | 1 |
| Ma, H | 1 |
| Chen, Y | 1 |
| Ma, ZM | 1 |
| Li, QZ | 1 |
| Peng, QS | 1 |
| Zhang, Y | 1 |
| Wang, SX | 1 |
| Sasaki, K | 1 |
| Ueno, T | 1 |
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
| Philipp, S | 1 |
| Böse, D | 1 |
| Wijns, W | 1 |
| Marso, SP | 1 |
| Schwartz, RS | 1 |
| König, A | 1 |
| Lerman, A | 1 |
| Garcia-Garcia, HM | 1 |
| Serruys, PW | 1 |
| Erbel, R | 1 |
| Santilli, F | 1 |
| Mucci, L | 1 |
| Davì, G | 1 |
| Masumura, Y | 1 |
| Ueda, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Rybicka, J | 1 |
| Kowalski, M | 1 |
| Michałowska, I | 1 |
| Hoffman, P | 1 |
| Reinhart, WH | 1 |
| Zhang, H | 1 |
| Guo, C | 1 |
| Zhang, A | 1 |
| Fan, Y | 1 |
| Gu, T | 1 |
| Wu, D | 1 |
| Sparatore, A | 1 |
| Donaldson, CW | 1 |
| Schneider, DJ | 1 |
| Bertges, DJ | 1 |
| Adams, JE | 1 |
| Elgharib, NZ | 1 |
| Mueller, EL | 1 |
| Prabhu, W | 1 |
| Ashikaga, T | 1 |
| Dauerman, HL | 1 |
| White, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome[NCT02041650] | Phase 4 | 250 participants (Anticipated) | Interventional | 2014-08-31 | Completed | ||
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for aspirin and Atheroma
| Article | Year |
|---|---|
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Hemorrhage; Huma | 2021 |
[Atherothrombosis : Novel therapeutic strategies].
Topics: Animals; Anticoagulants; Aspirin; Carrier Proteins; Clinical Trials as Topic; Humans; Hydroxymethylg | 2018 |
Antithrombotic Agents.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a | 2019 |
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Plaque, Atherosclerotic; Platele | 2011 |
Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Fibrin; Humans; Plaque, Atherosclerotic; Platel | 2014 |
6 trials available for aspirin and Atheroma
| Article | Year |
|---|---|
Dengzhan Shengmai capsule versus Aspirin in the treatment of carotid atherosclerotic plaque: A single-centre, non-inferiority, prospective, randomised controlled trial.
Topics: Aspirin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drugs, Chinese H | 2022 |
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Drug Resistance; Female; Hu | 2018 |
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia; | 2014 |
Aterofisiol(®) in carotid plaque evolution.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Dietary Supplements; Double-Blind Method; Endarterectomy, Ca | 2015 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
Increased local cytokine production at culprit superficial femoral artery plaques.
Topics: Aspirin; CD40 Ligand; Clopidogrel; Constriction, Pathologic; Female; Femoral Artery; Humans; Hydroxy | 2013 |
26 other studies available for aspirin and Atheroma
| Article | Year |
|---|---|
Atherothrombosis-on-Chip: A Site-Specific Microfluidic Model for Thrombus Formation and Drug Discovery.
Topics: Aspirin; Drug Discovery; Humans; Microfluidics; Plaque, Atherosclerotic; Reproducibility of Results; | 2022 |
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
Topics: Aminopyridines; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Morpholines; Oxazines; Plaque, | 2022 |
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Plaque, Atheroscleroti | 2023 |
Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Centella; D | 2020 |
Central cardiovascular calcifications: supplementation with Pycnogenol® and Centellicum®: variations over 12 months.
Topics: Aspirin; Cardiovascular Diseases; Centella; Coronary Artery Disease; Dietary Supplements; Disease Ma | 2020 |
A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Pr | 2020 |
Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cytokines; Endothelial Cells; Extracellular Vesicles; Hea | 2021 |
Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asymptomatic Diseases; Coronary Artery Disea | 2017 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; C | 2017 |
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fem | 2018 |
[Optical Coherence Tomography in ST-Elevation Myocardial Infarction].
Topics: Aged, 80 and over; Aspirin; Coronary Angiography; Coronary Artery Disease; Diagnosis, Differential; | 2018 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Re | 2019 |
Aspirin for primary prevention of atherothrombotic vascular events: how much "conclusive" is "conclusive?".
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Plaque, Atherosclerotic; Platelet Aggregation Inh | 2013 |
Is carotid ultrasound necessary in the evaluation of the asymptomatic Hollenhorst plaque?
Topics: Arterioles; Aspirin; Asymptomatic Diseases; Carotid Arteries; Carotid Stenosis; Endarterectomy, Caro | 2013 |
Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins E; Aspirin; Atherosclerosis; Cyclo | 2014 |
Long-term prognostic impact of the attenuated plaque in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Corona | 2016 |
Evaluation of aspirin resistance and the presence of unstable carotid plaque in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Carotid Stenosis; Endarterectomy, Carotid; | 2015 |
[Influence of coronary CT angiography findings on prevention strategies of coronary artery disease].
Topics: Aspirin; Cholesterol; Coronary Angiography; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-C | 2015 |
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Dr | 2016 |
Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins E; Aspirin; Atherosclerosis; Cells | 2016 |
[CHARISMA study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Embolism; Female; Humans; Male; Middle Aged; Plaque, | 2016 |
Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetic Angiopathies; Dyslipidemias | 2010 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
[Ulcerated plaques of the aorta as a cause of ischaemic stroke].
Topics: Acenocoumarol; Aspirin; Echocardiography; Foramen Ovale, Patent; Humans; Hydroxymethylglutaryl-CoA R | 2012 |
Platelets in vascular disease.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic; | 2013 |
Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice.
Topics: Animals; Apolipoproteins E; Aspirin; Atherosclerosis; Brachiocephalic Trunk; Cell Line; Chemotaxis; | 2012 |